Prise en charge du cancer rénal métastatique

25 novembre 2008

Auteurs : A. Méjean, T. Lebret
Référence : Prog Urol, 2008, 18, S298, suppl. S7
   
 
 

 

 
Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser

   

 

 
 
 

Références

 

Zisman A., Pantuck A.J., Wieder J., Chao D.H., Dorey F., Said J.W., deKernion J.B., Figlin R.A., Belldegrun A.S. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma J Clin Oncol 2002 ;  20 : 4559-4566 [cross-ref]
 
Raj G.V., Thompson R.H., Leibovich B.C., Blute M.L., Russo P., Kattan M.W. Preoperative nomogram predicting 12-year probability of metastatic renal cancer J Urol 2008 ;  179 : 2146-2151 [cross-ref]
 
Eggener S.E., Yossepowitch O., Pettus J.A., Snyder M.E., Motzer R.J., Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease:predicting survival from time of recurrence J Clin Oncol 2006 ;  24 : 3101-3106 [cross-ref]
 
Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics 2007 CA Cancer J Clin 2007 ;  57 : 43-66 [cross-ref]
 
Patard J.J., Tazi H., Bensalah K., Rodriguez A., Vincendeau S., Rioux-Leclercq N., Guillé F., Lobel B. The changing evolution of renal tumours: a single center experience over a two-decade period Eur Urol 2004 ;  45 : 490-493 [cross-ref]
 
Janzen N.K., Kim H.L., Figlin R.A., Belldegrun A.S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 2003 ;  30 : 843-852 [inter-ref]
 
Antonelli A., Cozzoli A., Zani D., Zanotelli T., Nicolai M., Cunico S.C., Simeone C. The follow-up management of non-metastatic renal cell carcinoma:definition of a surveillance protocol BJU Int 2007 ;  99 : 296-300 [cross-ref]
 
Hoffmann N.E., Gillett M.D., Cheville J.C., Lohse C.M., Leibovich B.C., Blute M.L. Differences in organ system of distant metastasis by renal cell carcinoma subtype J Urol 2008 ;  179 : 474-477 [cross-ref]
 
Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 2007 ;  356 : 115-124 [cross-ref]
 
Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. TARGET Study Group Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 2007 ;  356 : 125-134 [cross-ref]
 
Escudier B., Pluzanska A., Koralewski P., et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 2007 ;  370 : 2103-2111 [cross-ref]
 
Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. ECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma:a double-blind, randomised, placebo-controlled phase III trial Lancet 2008 ;  372 : 449-456 [cross-ref]
 
Doublet J.D. Le sous-comité rein. Adrenal gland tumors Prog Urol 2004 ;  14 (1037) : 1039-1041
 
Siemer S., Lehmann J., Kamradt J., Loch T., Remberger K., Humke U., Ziegler M., Stöckle M. Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy J Urol 2004 ;  171 : 2155-2159 [cross-ref]
 
Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 1999 ;  17 : 2530-2540
 
Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 2002 ;  20 : 289-296 [cross-ref]
 
Négrier S., Escudier B., Gomez F., Douillard J.Y., Ravaud A., Chevreau C., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie Ann Oncol 2002 ;  13 : 1460-1468
 
Raj G.V., Thompson R.H., Leibovich B.C., Blute M.L., Russo P., Kattan M.W. Preoperative nomogram predicting 12-year probability of metastatic renal cancer J Urol 2008 ;  179 : 2146-2151 [cross-ref]
 
Herold C.J., Bankier A.A., Fleischmann D. Lung metastases Eur Radiol 1996 ;  6 : 596-606
 
Mejean A., Correas J.M., Escudier B., de Fromont M., Lang H., Long J.A., et al. Kidney tumors Prog Urol 2007 ;  17 : 1101-1144 [cross-ref]
 
Shvarts O., Lam J.S., Kim H.L., Han K.R., Figlin R., Belldegrun A. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans J Urol 2004 ;  172 : 867-870 [cross-ref]
 
Sellner F., Tykalsky N., De Santis M., Pont J., Klimpfinger M. Solitary and multiple isolated metastases of clear cell renal carcinoma to the pancreas: an indication for pancreatic surgery Ann Surg Oncol 2006 ;  13 : 75-85 [cross-ref]
 
Kavolius J.P., Mastorakos D.P., Pavlovich C., Russo P., Burt M.E., Brady M.S. Resection of metastatic renal cell carcinoma J Clin Oncol 1998 ;  16 : 2261-2266 [cross-ref]
 
Kierney P.C., van Heerden J.A., Segura J.W., Weaver A.L. Surgeon’s role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review Ann Surg Oncol 1994 ;  1 : 345-352 [cross-ref]
 
Piltz S., Meimarakis G., Wichmann M.W., Hatz R., Schildberg F.W., Fuerst H. Long-term results after pulmonary resection of renal cell carcinoma metastases Ann Thorac Surg 2002 ;  73 : 1082-1087 [cross-ref]
 
Cerfolio R.J., Allen M.S., Deschamps C., Daly R.C., Wallrichs S.L., Trastek V.F., Pairolero P.C. Pulmonary resection of metastatic renal cell carcinoma Thorac Surg 1994 ;  57 : 339-344 [cross-ref]
 
Pfannschmidt J., Hoffmann H., Muley T., Krysa S., Trainer C., Dienemann H. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma Ann Thorac Surg 2002 ;  74 : 1653-1657 [cross-ref]
 
Tanguay S., Swanson D.A., Putnam J.B. Renal cell carcinoma metastatic to the lung:potential benefit in the combination of biological therapy and surgery J Urol 1996 ;  156 : 1586-1589 [cross-ref]
 
Nelson B.A., Sprunger J.K., Ninan M., Herrell S.D. Simultaneous thoracoscopic wedge resection of a solitary lung nodule and laparoscopic partial nephrectomy for a renal mass Urology 2004 ;  64 : 377-378 [inter-ref]
 
Shiono S., Yoshida J., Nishimura M., Nitadori J., Ishii G., Nishiwaki Y., Nagai K. Late pulmonary metastasis of renal cell carcinoma resected 25 years after nephrectomy Jpn J Clin Oncol 2004 ;  34 : 46-49 [cross-ref]
 
Won K.S., Marom E.M., Tateishi U., Namwongprom S., Kim E.E. Pulmonary arteriovenous fistula arising in a renal cell carcinoma lung metastasis Clin Radiol 2007 ;  62 : 812-816 [cross-ref]
 
Kopetz S., Jimenez C., Tu S.M., Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma Eur Respir J 2007 ;  29 : 813-815 [cross-ref]
 
Jung S.T., Ghert M.A., Harrelson J.M., Scully S.P. Treatment of osseous metastases in patients with renal cell carcinoma Clin Orthop Relat Res 2003 ;  409 : 223-231 [cross-ref]
 
Kuruvath S., Naidu S., Bhattacharyya M., Benjamin J.C., O’Donovan D.G. Spinal metastasis from renal cell carcinoma. 31 years following nephrectomy-case report Clin Neuropathol 2007 ;  26 : 176-179 [cross-ref]
 
Rasco D.W., Assikis V., Marshall F. Integrating metastasectomy in the management of advanced urological malignancies-where are we in 2005? J Urol 2006 ;  176 : 1921-1926 [cross-ref]
 
Sundaresan N., Rothman A., Manhart K., Kelliher K. Surgery for solitary metastases of the spine: rationale and results of treatment Spine 2002 ;  27 : 1802-1806 [cross-ref]
 
Alves A., Adam R., Majno P., Delvart V., Azoulay D., Castaing D., Bismuth H. Hepatic resection for metastatic renal tumors: is it worthwhile? Ann Surg Oncol 2003 ;  10 : 705-710 [cross-ref]
 
Murakami R., Taniai N., Kumazaki T., Kobayashi Y., Ogura J., Ichikawa T. Rupture of a hepatic metastasis from renal cell carcinoma Clin Imaging 2000 ;  24 : 72-74 [cross-ref]
 
Shuch B., La Rochelle J.C., Klatte T., Riggs S.B., Liu W., Kabbinavar F.F., Pantuck A.J., Belldegrun A.S. Brain metastasis from renal cell carcinoma:presentation, recurrence, and survival Cancer 2008 ; 31
 
Vecil G.G., Lang F.F. Surgical resection of metastatic intraventricular tumors Neurosurg Clin N Am 2003 ;  14 : 593-606 [inter-ref]
 
Kased N., Huang K., Nakamura J.L., Sahgal A., Larson D.A., McDermott M.W., Sneed P.K. Gamma knife radiosurgery for brainstem metastases:the UCSF experience J Neurooncol 2008 ;  86 : 195-205 [cross-ref]
 
Rini B.I., Vogelzang N.J., Dumas M.C., Wade J.L., Taber D.A., Stadler W.M. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer J Clin Oncol 2000 ;  18 : 2419-2426 [cross-ref]
 
Stadler W.M. Cytotoxic chemotherapy for metastatic renal cell carcinoma Urologe A 2004 ;  43 : 145-146 [cross-ref]
 
Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone N Engl J Med 1987 ;  316 : 889-897 [cross-ref]
 
Law T.M., Motzer R.J., Mazumdar M., Sell K.W., Walther P.J., O’Connell M., et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma Cancer 1995 ;  76 : 824-832 [cross-ref]
 
Weiss G.R., Margolin K.A., Aronson F.R., Sznol M., Atkins M.B., Dutcher J.P., et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma J Clin Oncol 1992 ;  10 : 275-281 [cross-ref]
 
West W.H., Tauer K.W., Yannelli J.R., Marshall G.D., Orr D.W., Thurman G.B., Oldham R.K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer N Engl J Med 1987 ;  316 : 898-905 [cross-ref]
 
Negrier S., Escudier B., Lasset C., Douillard J.Y., Savary J., Chevreau C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renalcell carcinoma. Groupe Français d’Immunothérapie N Engl J Med 1998 ;  338 : 1272-1278 [cross-ref]
 
Coppin C., Porzsolt F., Awa A., Kumpf J., Coldman A., Wilt T. Immunotherapy for advanced renal cell cancer Cochrane Database Syst Rev 2005 ; CD001425.
 
Negrier S., Perol D., Ravaud A., Chevreau C., Bay J.O., Delva R., Sevin E., Caty A., Escudier B.For The French Immunotherapy Intergroup Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial Cancer 2007 ;  110 : 2468-2477
 
Rak J., Kerbel R.S. Ras regulation of vascular endothelial growth factor and angiogenesis Methods Enzymol 2001 ;  333 : 267-283 [cross-ref]
 
Hilger R.A., Scheulen M.E., Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer Onkologie 2002 ;  25 : 511-518 [cross-ref]
 
Oka H., Chatani Y., Hoshino R., Ogawa O., Kakehi Y., Terachi T., et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma Cancer Res 1995 ;  55 : 4182-4187
 
Eisenmann K.M., VanBrocklin M.W., Staffend N.A., Kitchen S.M., Koo H.M. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad Cancer Res 2003 ;  63 : 8330-8337
 
Wang H.G., Rapp U.R., Reed J.C. Bcl-2 targets the protein kinase Raf-1 to mitochondria Cell 1996 ;  87 : 629-638 [cross-ref]
 
Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin Mol Cell Biol 2002 ;  22 : 7004-7014 [cross-ref]
 
Meric-Bernstam F., Mills G.B. Mammalian target of rapamycin Semin Oncol 2004 ;  31 : 10-17 [cross-ref]
 
Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., Czernin J., Sawyers C.L. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Nat Med 2006 ;  12 : 122-127 [cross-ref]
 
Atkins M.B., Hidalgo M., Stadler W.M., Logan T.F., Dutcher J.P., Hudes G.R., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 2004 ;  22 : 909-918 [cross-ref]
 
Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 2007 May ;  356 : 2271-2281 [cross-ref]
 
Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 2003 ;  9 : 327-337
 
Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 2006 ;  24 : 16-24 [cross-ref]
 
Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma JAMA 2006 ;  295 : 2516-2524 [cross-ref]
 
Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 2007 ;  99 : 81-83 [cross-ref]
 
Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 2004 ;  64 : 7099-7109 [cross-ref]
 
Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 2006 ;  24 : 2505-2512 [cross-ref]
 
Presta L.G., Chen H., O’Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 1997 ;  57 : 4593-4599
 
Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 2003 ;  349 : 427-434 [cross-ref]
 
Tamaskar I., Garcia J.A., Elson P., et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy J Urol 2008 ;  179 : 81-86 [cross-ref]
 
Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 2008 ;  8 : 592-603 [cross-ref]
 
Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in latestage pancreatic islet tumors Cancer Cell 2005 ;  8 : 299-309 [cross-ref]
 
Rubenstein J.L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D.F., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption Neoplasia 2000 ;  2 : 306-314 [cross-ref]
 
Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 2001 ;  7 : 987-989 [cross-ref]
 
Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 2001 ;  345 : 1655-1659 [cross-ref]
 
Mickisch G.H., Garin A., van Poppel H., de Prijck L., Sylvester R.European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma:a randomized trial Lancet 2001 ;  358 : 966-970 [cross-ref]
 
Flanigan R.C., Mickisch G., Sylvester R., Tangen C., Van Poppel H., Crawford E.D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 2004 ;  171 : 1071-1076 [cross-ref]
 
Pantuck A.J., Belldegrun A.S., Figlin R.A. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin Cancer Res 2007 ;  13 : 693s-696s
 
Rini B.I., Campbell S.C. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy J Urol 2007 ;  177 : 1978-1984 [cross-ref]
 
   
 
 
   

 

© 2008  Elsevier Masson SAS. Tous droits réservés.